Cadrenal Therapeutics, Inc.
CVKD · XNASCIK 1937993fmd_0N4TZMSC8M73YRBKK5QMNSVT80Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Apr 01, 2007 to Jun 30, 2026, 18 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cost of revenue | 0 | – | – |
| Research and development | 4 | 4 | 4 |
| Total operating expenses | 8 | 11 | 13 |
| Operating income | (8) | (11) | (13) |
| Interest expense | 0 | – | – |
| Interest and investment income | 0 | 0 | 0 |
| Other non-operating income (expense) | (1) | 0 | 0 |
| Net income | (8) | (11) | (13) |
| Net income to common shareholders | (8) | (11) | (13) |